Abstract
Glucagon-like peptide-1 (GLP-1) is a short peptide that can significantly reduce blood glucose level. Recombination oral long-acting glucagon-like peptide-1 (rolGLP-1), is a GLP-1 analog generated from site-specific mutation of GLP-1. CTB is a non-toxic portion of the cholera toxin and an ideal protein antigen carrier. In this study, we firstly constructed a vector pET-22b (+)-CTB-10×rolGLP-1 to express a fusion protein composed of CTB and ten tandem repeated rolGLP-1 in BL21 (DE3) line of E.coli. The CTB-10×rolGLP-1 was expressed efficiently in the inclusion bodies. The expression product was analyzed by SDS-PAGE electrophoresis and Western blotting. The inclusion bodies were then denatured, refolded and purified by ion exchange chromatography to obtain a high-purity CTB- 10×rolGLP-1. The therapeutic effect of CTB-10×rolGLP-1 was assessed in comparison with 10×rolGLP-1 alone by daily oral-gavage administration up to 10 days in streptozotocin-induced type 2 diabetic mice. The results showed that the level of blood glucose was reduced more effectively and the oral glucose tolerance of mice was improved more significantly with the administration of CTB-10×rolGLP-1. Our results provided a potentially promising oral biological drug for the treatment of type 2 diabetes.
Keywords: Diabetes mellitus, CTB, rolGLP-1, 10×rolGLP-1, fusion polypeptide.
Current Pharmaceutical Biotechnology
Title:Expression of CTB-10×rolGLP-1 in E.coli and Its Therapeutic Effect on Type 2 Diabetes
Volume: 16 Issue: 6
Author(s): Peipei Tu, Zhihua Ma, Haisong Wang, Baicheng Ma, Xiaodan Li, Huikun Duan, Pingzhe Jiang, Miao Li, Ri Wu, Jianhong Zhu and Minggang Li
Affiliation:
Keywords: Diabetes mellitus, CTB, rolGLP-1, 10×rolGLP-1, fusion polypeptide.
Abstract: Glucagon-like peptide-1 (GLP-1) is a short peptide that can significantly reduce blood glucose level. Recombination oral long-acting glucagon-like peptide-1 (rolGLP-1), is a GLP-1 analog generated from site-specific mutation of GLP-1. CTB is a non-toxic portion of the cholera toxin and an ideal protein antigen carrier. In this study, we firstly constructed a vector pET-22b (+)-CTB-10×rolGLP-1 to express a fusion protein composed of CTB and ten tandem repeated rolGLP-1 in BL21 (DE3) line of E.coli. The CTB-10×rolGLP-1 was expressed efficiently in the inclusion bodies. The expression product was analyzed by SDS-PAGE electrophoresis and Western blotting. The inclusion bodies were then denatured, refolded and purified by ion exchange chromatography to obtain a high-purity CTB- 10×rolGLP-1. The therapeutic effect of CTB-10×rolGLP-1 was assessed in comparison with 10×rolGLP-1 alone by daily oral-gavage administration up to 10 days in streptozotocin-induced type 2 diabetic mice. The results showed that the level of blood glucose was reduced more effectively and the oral glucose tolerance of mice was improved more significantly with the administration of CTB-10×rolGLP-1. Our results provided a potentially promising oral biological drug for the treatment of type 2 diabetes.
Export Options
About this article
Cite this article as:
Tu Peipei, Ma Zhihua, Wang Haisong, Ma Baicheng, Li Xiaodan, Duan Huikun, Jiang Pingzhe, Li Miao, Wu Ri, Zhu Jianhong and Li Minggang, Expression of CTB-10×rolGLP-1 in E.coli and Its Therapeutic Effect on Type 2 Diabetes, Current Pharmaceutical Biotechnology 2015; 16 (6) . https://dx.doi.org/10.2174/138920101606150407114815
DOI https://dx.doi.org/10.2174/138920101606150407114815 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Editorial [Hot Topic: Trends in Vascular Biology; Functional Restoration of Damaged Endothelium (Executive Editors: J.A. Rodriguez-Feo and G. Pasterkamp)]
Current Pharmaceutical Design Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Potential Applications of Vasoactive Intestinal Peptide-Based Therapies on Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Enhanced Butyrylcholinesterase Activity may be the Common Link in Triggering Low-Grade Systemic Inflammation and Decrease in Cognitive Function in Diabetes Mellitus and Alzheimers disease
Current Nutrition & Food Science The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Cardiovascular & Hematological Disorders-Drug Targets Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Pharmacologic Vitreolysis in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal